OTC Heartburn Drug Uniform Warnings Advocated By Advisory Panels
This article was originally published in The Tan Sheet
Executive Summary
All OTC heartburn medications should carry stronger warnings alerting consumers about when they may be suffering from a more serious condition, members of FDA's Nonprescription and Gastrointestinal Drugs Advisory Committees recommended
You may also be interested in...
Two GDAC Members Weigh In On Prilosec 1 Without Voting
An upcoming publication by FDA's Gastrointestinal Drugs Advisory Committee chairman will suggest a potential link between proton pump inhibitor therapy and the proliferation of pre-existing esophageal adenocarcinoma
Two GDAC Members Weigh In On Prilosec 1 Without Voting
An upcoming publication by FDA's Gastrointestinal Drugs Advisory Committee chairman will suggest a potential link between proton pump inhibitor therapy and the proliferation of pre-existing esophageal adenocarcinoma
Two GDAC Members Weigh In On Prilosec 1 Without Voting
An upcoming publication by FDA's Gastrointestinal Drugs Advisory Committee chairman will suggest a potential link between proton pump inhibitor therapy and the proliferation of pre-existing esophageal adenocarcinoma